Search Menu

Paul Moser

Paul trained as a pharmacologist in the UK, first in Bristol, then in Bath for his Ph.D., specialising in chronopharmacology. He has spent over 30 years in the pharma industry in both big and medium pharma companies, biotech and also in contract research. After a few …

Read more

Rita Balice-Gordon

Rita Balice-Gordon, Ph.D., is the Global Head, Rare and Neurologic Diseases Research Therapeutic Area at Sanofi, Inc.  She leads groups of scientists based in Boston and Paris working on small molecules, antibodies and gene therapy as modalities for discovering and developing innovative and transformative therapeutics for patients …

Read more

Phil Skolnick

Dr. Skolnick is the Chief Scientific Officer at Opiant Pharmaceuticals, Inc. Prior to joining Opiant, he was the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017).  He served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, …

Read more

Scroll Up